Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 554-57-4
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of methazolamide during breastfeeding. The American, Canadian and French professional guidelines consider carbonic anhydrase inhibitors acceptable in breastfeeding.[1,2] However, an alternate drug with more published information may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
- 1.
- Belkin A, Chen T, DeOliveria AR, et al. A practical guide to the pregnant and breastfeeding patient with glaucoma. Ophthalmol Glaucoma 2020;3:79-89. [PubMed: 32672600]
- 2.
- Blumen-Ohana E, Sellem E. Pregnancy & glaucoma: SFO-SFG recommendations. J Fr Ophtalmol 2020;43:63-6. [PubMed: 31813552]
Substance Identification
Substance Name
Methazolamide
CAS Registry Number
554-57-4
Drug Class
Breast Feeding
Lactation
Milk, Human
Antiglaucoma Agents
Carbonic Anhydrase Inhibitors
Diuretics
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.